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The inflammatory responses of resident central nervous system (CNS) cells are now
known to play a critical role in the initiation and progression of an array of infectious
and sterile neuroinflammatory disorders such as meningitis, encephalitis, Parkinson’s
disease, Alzheimer’s disease and multiple sclerosis (MS). Regulating glial inflammatory
responses in a timely manner is therefore critical in preserving normal CNS functions.
The neuropeptide substance P is produced at high levels within the CNS and its
selective receptor, the neurokinin 1 receptor (NK-1R), is abundantly expressed by
neurons and is present on glial cell types including microglia and astrocytes. In addition
to its functions as a neurotransmitter in the perception of pain and its essential
role in gut motility, this tachykinin is widely recognized to exacerbate inflammation
at peripheral sites including the skin, gastrointestinal tract and the lungs. Recently, a
number of studies have identified a role for substance P and NK-1R interactions in
neuroinflammation and described the ability of this neuropeptide to alter the immune
functions of activated microglia and astrocytes. In this review article, we describe
the expression of substance P and its receptor by resident CNS cells, and we
discuss the ability of this neuropeptide to exacerbate the inflammatory responses
of glia and immune cells that are recruited to the brain during neurodegenerative
diseases. In addition, we discuss the available data indicating that the NK-1R-
mediated augmentation of such responses appears to be detrimental during microbial
infection and some sterile neurodegenerative disorders, and propose the repurposed
use of NK-1R antagonists, of a type that are currently approved as anti-emetic and
anti-anxiolytic agents, as an adjunct therapy to ameliorate the inflammatory CNS damage
in these conditions.
Keywords: substance P, neuroinflammation, neuropeptide, neurokinin-1 receptor, tachykinin, microglia,
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Substance P is a member of the tachykinin family of neuropeptides that share common
pharmacological properties and a conserved carboxyl-terminal sequence (Phe-X-Gly-Leu-Met-
NH2, X hydrophobic or aromatic; Harrison and Geppetti, 2001). The carboxyl-terminal sequence
is required for interaction with tachykinin receptors and cellular activation, while the distinct
amino-terminal confers receptor subtype specificity (Gerard et al., 1991). The tachykinins are
expressed broadly throughout the nervous and immune systems (Harrison and Geppetti, 2001;
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Satake and Kawada, 2006). Accordingly, these neuropeptides
mediate a diverse range of physiological and pathological
processes, and this has made them attractive targets for
therapeutic intervention. The major mammalian tachykinins
are substance P, neurokinin A, neurokinin B, neuropeptide K
and neuropeptide gamma (Steinhoff et al., 2014). Of these,
substance P is of particular interest as a target for the
treatment of a variety of diseases due to its widespread
distribution and its ability to induce inflammation, in contrast
to other neuropeptides such as vasoactive intestinal peptide
and pituitary adenylate cyclase-activating polypeptide that exert
anti-inflammatory effects (Padua et al., 2016).
The inflammatory effects of substance P are mediated via
interaction with its high affinity neurokinin-1 receptor (NK-1R;
Pernow, 1983; Maggi, 1997), a seven transmembrane domain
G-protein coupled receptor. While substance P preferentially
interacts with, and signals via, NK-1R, at high concentrations
it can also activate cells via neurokinin-2 and neurokinin-3
receptors (Regoli et al., 1994). Activation via NK-1R leads
to cell-type dependent responses such as endothelial cell
retraction and vascular smooth muscle dilation (Maggi, 1995;
Holzer, 1998; van Hinsbergh and van Nieuw Amerongen,
2002). Perhaps more importantly, substance P can stimulate
and/or modulate cytokine release by various cell types, and
there is compelling evidence that this neuropeptide plays a
critical role in modulating immune responses at peripheral
sites such as the gastrointestinal and respiratory tracts where
inflammation correlates with NK-1R activation (O’Connor
et al., 2004). In the gastrointestinal tract, substance P regulates
smooth muscle contractility, vascular permeability and immune
functions (Pernow, 1983; Lördal et al., 1996; O’Connor et al.,
2004). Elevated expression of substance P is associated with
gastrointestinal diseases such inflammatory bowel disease,
Trichinella spiralis-induced enteritis and Clostridium difficile
enterocolitis (Koch et al., 1987; Mazumdar and Das, 1992;
Swain et al., 1992; Agro and Stanisz, 1993; Bernstein et al.,
1993) and substance P levels correlate with symptom severity
in cryptosporidiosis (Robinson et al., 2003). The link between
substance P and damaging inflammation in the gut is
further supported by the demonstration that NK-1R blockade
abrogates intestinal inflammation associated with Clostridium
difficile toxin A and Trichinella spiralis-induced enteritis
(Swain et al., 1992; Agro and Stanisz, 1993; Kataeva et al.,
1994; Castagliuolo et al., 1998). Interestingly, the presence
of proinflammatory cytokines can further induce the level
of expression of NK-1R by colonic epithelial cells suggesting
that positive feedback loops may exist to potentiate the
pro-inflammatory actions of substance P in the gastrointestinal
tract (Goode et al., 2003). Similarly, in the respiratory tract,
interactions between substance P and NK-1R have been shown
to augment inflammatory processes where this neuropeptide
can increase immune cell infiltration and the release of
cytokines that contribute to disease pathology in asthma and
respiratory syncytial virus infection (Nadel, 1991; King et al.,
2001).
As we discuss in the present review, substance P is the most
abundant tachykinin in the brain (Pernow, 1983; Severini et al.,
2002) and NK-1R can be expressed by non-neuronal cells of the
central nervous system (CNS), such as astrocytes and microglia,
that have important immune functions (Michel et al., 1986;
Beaujouan et al., 1991; Marriott andWilkin, 1993; Lai et al., 2000;
Rasley et al., 2002b). Similar to reports in the gastrointestinal
and respiratory tract, substance P has been shown to augment
inflammation in the CNS (Lee et al., 1994; Rasley et al., 2004b;
Chauhan et al., 2008). This ability, and the availability of
centrally acting NK-1R inhibitors that are approved for use
in human subjects, raises the intriguing possibility that the
targeting of substance P/NK-1R interactions could be useful as
an adjunctive therapy for the treatment of neuroinflammatory
disorders.
LOCALIZATION OF SUBSTANCE P AND
NK-1R WITHIN THE CNS
Tachykinins were originally named for their ability to stimulate
contraction of intestinal muscle in the seminal work by
V Euler and Gaddum (1931) in which ‘‘preparation P’’,
later renamed substance P, isolated from horse intestine and
brain induced isolated rabbit jejunum contraction. It is now
appreciated that substance P and its receptor are found in high
quantities throughout the CNS. Substance P immunoreactivity
was observed in the CNS as early as the mid-1970s (Hökfelt
et al., 1975; Cuello and Kanazawa, 1978; Ljungdahl et al.,
1978a,b; Cuello et al., 1979) and neuroanatomical analysis of
substance P distribution in the rat CNS revealed the highest
levels in the substantia nigra and the medial amygdaloid nucleus
of the brain, and in the superficial dorsal horn of the spinal
cord (Ribeiro-da-Silva and Hökfelt, 2000). The presence of
substance Pwithin the primary sensory neurons of the brainstem,
cranial nerve nuclei, and spinal cord dorsal horn (Cuello and
Kanazawa, 1978; Cuello et al., 1979, 1993; Douglas and Leeman,
2011) is consistent with its role as a sensory neurotransmitter
important for the perception of pain (Douglas and Leeman,
2011).
However, substance P is found in many other regions of
the brain including the hippocampus, cortex, basal ganglia and
hypothalamus (Ebner and Singewald, 2006), and can produce
effects throughout the CNS. Furthermore, this tachykinin is
also broadly distributed throughout the peripheral nervous
system and enteric nervous system, and can be expressed by
cells of the immune system. Specifically, substance P can be
expressed by peripheral leukocytes including lymphocytes and
monocytes/macrophages (Bost et al., 1992; Bost, 1995; Ho et al.,
1997; Lai et al., 1998; Chernova et al., 2009).
NK-1R is a G-protein coupled receptor and has the highest
affinity for substance P over other tachykinin receptors and is
found as two isoforms; a full-length form (407 amino acids)
and a truncated form (311 amino acids; Fong et al., 1992; Baker
et al., 2003). The truncated form of NK-1R binds substance P
with 10-fold lower affinity than the long form (Douglas and
Leeman, 2011). Substance P binding to full-length NK-1R
stimulates phosphorylation of the C-terminus via G-protein
receptor kinases and protein kinase C to activate members of
the mitogen-activated protein kinase (MAPK) cascade, including
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extracellular signal-regulated kinases 1 and 2, and p38 MAPK (as
reviewed in Steinhoff et al., 2014). Importantly, in immune cells
such as macrophages, activation of MAPK cascades precipitates
activation of NF-kB, the master regulator of immune mediator
production (Sun et al., 2008). Hence, through activation of
NF-κB, substance P can augment inflammation by stimulating
the production of proinflammatory cytokines (Bost, 2004a).
In contrast, the truncated NK-1R lacks the majority of the
C-terminus and is not phosphorylated following substance P
binding. Accordingly, signaling via this truncated form does
not result in NF-kB activation, and fails to elicit cellular effects
including desensitization, endocytosis, endosomal signaling
changes and production of inflammatory chemokines such as
IL-8 (DeFea et al., 2000; Lai et al., 2008). However, the truncated
NK-1R form may have biological functions beyond serving as a
decoy receptor, and has been suggested to provide or augment
a persistent growth stimulus to cancer cells (Gillespie et al.,
2011).
Substance P mediates numerous and cell-type specific
effects throughout the body due to the broad expression of
NK-1R in many cell types and tissues. Like substance P,
NK-1R expression is widely distributed throughout the CNS
as determined by autoradiography, in situ hybridization and
immunohistochemical approaches (Mantyh et al., 1984, 1989;
Nakaya et al., 1994; Caberlotto et al., 2003). NK-1R mRNA
is found in the olfactory bulb, cerebral cortex, medulla
oblongata and spinal cord in mice (Andoh et al., 1996).
Initial studies of human brain revealed high levels of NK-1R
expression in the locus coeruleus and ventral striatum, moderate
expression in the cerebral cortex, hippocampus and amygdaloid
nuclei, and only low levels in the cerebellum and thalamus
(Caberlotto et al., 2003). Further studies, using positron
emission tomographic analysis of healthy human males using
a high-affinity 18F labeled-NK-1R antagonist, suggested that
the highest levels of cellular NK-1R expression normally occur
in the caudate and the putamen, regions of the brain in
close proximity to the amygdaloid nucleus (Hietala et al.,
2005). The constitutive expression and anatomical location of
this neuropeptide and its receptor in the limbic system of
the healthy brain suggest that substance P/NK-1R interactions
play an integral role in complex CNS processing, and the
neurotransmitter/neuromodulatory functions of this tachykinin
have recently been reviewed elsewhere (Garcia-Recio and
Gascón, 2015).
It is noteworthy that there has been considerable recent
interest in defining the location of NK-1R expressing cells with
the recognition that substance P may not act as a classical
neurotransmitter. Rather, there are anatomical mismatches
between substance P release sites and responsive cells (Liu
et al., 1994; Nakaya et al., 1994). Liu et al. (1994) determined
that many substance P receptors had non-synaptic localizations
within the rat CNS. The ability of substance P to diffuse
and act upon distant cells suggests that this neuropeptide
could have endocrine characteristics within the CNS and
beyond. The relevance of this is underscored by the fact that
numerous non-neuronal cell types, such as smooth muscle
cells, fibroblasts, keratinocytes and endothelial cells, functionally
express NK-1R. Importantly, glial cells with immune functions
and leukocytes recruited to the CNS also express NK-1R,
either constitutively or following activation (Schaffer et al.,
1998), and so may be susceptible to the pro-inflammatory
actions of this neuropeptide. However, it should be noted
that the cellular expression of the truncated NK-1R form can
also be dynamic (Vilisaar et al., 2015), and few studies have
distinguished between the full length and truncated form of this
receptor.
SUBSTANCE P PROMOTES LEUKOCYTE
RECRUITMENT AND ACTIVATION
While the CNS is extensively protected by the blood-brain
barrier, inflammation within the brain leads to the infiltration
of peripheral macrophages, dendritic cells, T cells and other
immune responders (Hickey, 1999; Whitney et al., 2009), and it
is well recognized that there is extensive crosstalk between the
nervous system and the immune system. Trauma and infections
of the CNS are characterized by high levels of inflammatory
mediators such as cytokines (Ziebell and Morganti-Kossmann,
2010), and immunomodulatory neuropeptides including
substance P can affect the release of cytokines by immune
cells (Lee et al., 1994; Ho et al., 1996). In turn, inflammatory
cytokines can regulate the release of substance P and expression
of NK-1R by leukocytes, further sensitizing these cells to the
effects of substance P in a positive feedback loop-like manner
(Marriott and Bost, 2000; Blum et al., 2001, 2008; Weinstock
et al., 2003a).
The interaction of substance P with NK-1R triggers
neurogenic inflammation and directly augments inflammatory
processes in the lung, gut, skin and other peripheral organs
(Steinhoff et al., 2014). Neurogenic inflammation is characterized
by vasodilation and increased vascular permeability leading
to increased immune cell infiltration (Brown and Neher,
2010). Substance P promotes inflammation in at least
three ways as recently discussed by Corrigan et al. (2016).
First, substance P elicits vasodilation and increases vascular
permeability. Second, this neuropeptide can facilitate leukocyte
extravasation by inducing the expression of adhesion molecules
necessary for immune cell adherence to endothelial cells,
and by subsequently promoting their migration to the site
of injury or infection. Third, substance P can act directly on
resident and/or infiltrating cells to augment their immune
functions.
Early reports identified the expression of substance P
and/or NK-1R by peripheral human lymphocytes and
monocytes/macrophages (Bost et al., 1992; Ho et al., 1997;
Lai et al., 1998). Since these studies, natural killer cells,
dendritic cells, mast cells and neutrophils have been added
to the list and have been shown to either express NK-1R
or respond to substance P in an NK-1R-dependent manner
(Marriott and Bost, 2001a; O’Connor et al., 2004). Accordingly,
during an immune challenge, substance P produced by
immune and non-immune cell types can function as a
potent chemoattractant and promote the inflammatory
responses of a diverse range of cells including macrophages,
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dendritic cells, lymphocytes and eosinophils (O’Connor et al.,
2004). However, it should be noted that the mechanisms
underlying the actions of substance P on eosinophils are more
controversial as its effects have been reported to occur in a
receptor-independent manner, either via the N-terminus of
substance P or via interactions with epithelial cells (Kroegel et al.,
1990).
Substance P has been shown to also stimulate or
augment the production of inflammatory cytokines by
monocytes/macrophages, T lymphocytes and mast cells, and
can promote the release of inflammatory mediator-containing
granules of neutrophils, mast cells and eosinophils (Bill et al.,
1979; Shanahan et al., 1985; Lotz et al., 1988; Serra et al.,
1988; Kroegel et al., 1990; Calvo et al., 1992; Ho et al., 1996;
Marriott and Bost, 2001b). In addition, this neuropeptide can
also inhibit the production of the immunosuppressive cytokine
TGF-β1 by activated macrophages (Marriott and Bost, 1998)
providing another mechanism by which this tachykinin can
foster an inflammatory environment. Furthermore, substance P
has been reported to stimulate T-lymphocyte proliferation
and natural killer cell activity, and substance P may also
serve as a B-lymphocyte differentiation cofactor and augment
immunoglobulin secretion (Croitoru et al., 1990; Pascual and
Bost, 1990; Pascual et al., 1991a,b, 1992; Bost and Pascual, 1992;
Covas et al., 1994). As such, these studies indicate that this
neuropeptide has the potential to exacerbate both acute and
chronic inflammatory immune responses associated with the
recruitment of immune cells to the CNS.
Due to the dynamic crosstalk between the nervous system
and the immune system, it is perhaps not surprising that
the expression of both substance P and its receptor are
regulated by immune responses. The potent inflammatory
mediator IL-12, the related cytokine IL-23 and IL-18, can
all induce substance P production and NK-1R expression by
murine macrophages and T-lymphocytes (Blum et al., 2001,
2008; Weinstock et al., 2003a; Arsenescu et al., 2005). In
addition, a recent study has provided evidence for the reciprocal
positive regulation of IL-23 and IL-17 pathways and NK-1R
expression in human mononuclear cells (Vilisaar et al., 2015).
The ability of IL-12/IL-23 cytokines and IL-18 to induce NK-1R
expression can be explained due to the ability of both of
these cytokines to elicit cellular effects via NF-kB activation
(Weinstock et al., 2003a), and the fact that the promoter region
of the NK-1R gene contains a binding site for this transcription
factor (Takahashi et al., 1992). Similarly, other pro-inflammatory
cytokines including IFN-γ and TNF-α can elevate NK-1R
expression in macrophages, while this effect can also be achieved
with the signature T-helper type 2 cytokine, IL-4 (Marriott and
Bost, 2000).
In contrast, cytokines with anti-inflammatory functions,
such as IL-10 and TGF-β, have been reported to reduce
the expression of substance P and NK-1R in immune cells
(Weinstock et al., 2003b; Blum et al., 2008). However, caution
should be taken in designating the effects of pleiotropic
cytokines such as TGF-β. While TGF-β is generally considered
to be immunosuppressive, the presence of this cytokine
in combination with inflammatory cytokines, such as IL-6,
promotes the formation of proinflammatory TH17 T-cells
(Bettelli et al., 2006). Furthermore, there is evidence that this
cytokine can down-regulate NK-1R internalization by T-cells in
a mouse model of inflammatory bowel disease, and can enhance
signal transduction pathways used by effector T-cells to augment
inflammatory cytokine production (Beinborn et al., 2010).
SUBSTANCE P PROMOTES THE
INFLAMMATORY IMMUNE RESPONSES
OF RESIDENT CNS CELLS
The brain has typically been characterized as a victim organ
of infiltrating leukocytes, but it is increasingly appreciated that
resident glial cells play an essential role in the initiation and
progression of immune responses within the CNS. While, early
studies reported substance P immunoreactivity in cells and
tissues isolated from the CNS (Michel et al., 1986; Kostyk
et al., 1989), it is now recognized that non-neuronal CNS
cells can express both substance P and its receptor, either
constitutively or following exposure to inflammatory/damaging
stimuli, much like peripheral immune cells. Cortical and white
matter astrocytes express substance P and NK-1R (Michel et al.,
1986; Torrens et al., 1989; Beaujouan et al., 1991; Marriott
and Wilkin, 1993), and this receptor has also been detected
in human spinal cord astrocytes (Palma et al., 1997). Like
leukocytes, the expression of substance P and its receptor by
astrocytes is influenced by inflammatorymediators. For example,
levels of NK-1R expressed by a human astrocytic cell line
and rat primary astrocytes are elevated in response to the
potent inflammatory cytokine IL-1β, consistent with previous
observations that substance P binding sites are highly expressed
following neuronal injury (Guo et al., 2004).
While the expression of substance P receptors by neurons,
cerebral endothelial cells, and astrocytes is well established,
the expression of authentic substance P receptors on microglia
is more controversial. Luber-Narod et al. (1994) reported a
lack of detectable binding sites for radiolabeled substance P
on microglia, either at rest or following challenge with
bacterial lipopolysaccharide. Similarly, another study failed to
detect in vivo NK-1R expression by rat microglia following
ischemic brain injury as determined by in situ hybridization
and immunohistochemical staining approaches (Stumm et al.,
2001). In contrast, our own studies indicate that neonatal
mouse microglia express mRNA encoding NK-1R and we have
confirmed the presence of this receptor protein in this cell type by
Western blot analysis and flow cytometry (Rasley et al., 2002b).
Likewise, NK-1R has been specifically detected in human fetal
brain microglia and rat spinal microglia (Lai et al., 2000; Bradesi
et al., 2009).
Importantly, the interaction of substance P with NK-1R
appears to promote inflammatory immune responses by glia
in a similar manner to its effects on peripheral leukocytes.
Substance P activates the key inflammatory regulator NF-κB in
human astrocytoma cells (Lieb et al., 1997), and can elicit the
production of a number of inflammatory cytokines, including
IL-6, IL-8 and granulocytemacrophage colony-stimulating factor
(GM-CSF), and reactive oxygen intermediates by these cells
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and primary human embryonic and spinal astrocytes (Lieb
et al., 1997; Palma et al., 1997; Palma and Manzini, 1998).
Similarly, we have shown that this neuropeptide induces the
nuclear translocation of the RelA subunit of NF-kB (Rasley
et al., 2002b) in primary murine microglia, while Zhu et al.
(2014) have recently shown that exposure to substance P,
in combination with histamine, results in the production of
reactive oxygen species and the release of IL-6 and TNF-α by
these cells. Since microglia and astrocytes are susceptible to
the pro-inflammatory effects of substance P, this neuropeptide
appears to be capable of exacerbating the immune responses of
both resident CNS cells and recruited leukocytes in CNS damage
or disease.
EVIDENCE FOR THE INVOLVEMENT OF
SUBSTANCE P IN CNS DISORDERS
Given that both resident glia and infiltrating leukocytes can
express substance P and its receptor, either constitutively or
following exposure to immune mediators, and that substance P
is present at high levels throughout the CNS, it is perhaps
not surprising that this neuropeptide has been implicated
in the pathogenesis of a number of inflammatory CNS
disorders.
It is well known that CNS trauma and infection are
accompanied by widespread inflammation in the brain and
resident glial cells, including astrocytes and microglia, play a key
role in the initiation and propagation of this response (Corrigan
et al., 2016). Although protected extensively by the blood-brain
barrier, neuroinflammation leads to infiltration of peripheral
macrophages, dendritic cells, T cells, and other immune
responders (Hickey, 1999; Whitney et al., 2009). Activated glial
cells secrete a plethora of pro-inflammatory mediators including
PGE2 (Rasley et al., 2002a, 2004b), IL-12 (Rasley et al., 2004a),
IL-6, and TNF-α (Chauhan et al., 2009, 2010) resulting in
the disruption of the blood-brain barrier thereby facilitating
cellular infiltration (Hickey, 1999; Lossinsky and Shivers, 2004;
Taupin, 2008; Whitney et al., 2009). Accordingly, the ability of
substance P to induce vasodilation in the brain, promote the
recruitment of immune cells, and augment the inflammatory
responses of both infiltrating and resident cells, can contribute
to the development of devastating conditions such as meningitis
and encephalitis following infection (Maggi, 1995; O’Connor
et al., 2004; Corrigan et al., 2016).
A compelling body of evidence now suggests that interactions
between substance P and NK-1R exacerbate CNS inflammation
during parasitic, viral and bacterial infections. Neurocysticercosis
is a parasitic infection of the CNS caused by Taenia solium
that results in seizures in patients due to the granulomatous
host immune response to this pathogen. Analysis of biopsies
from human neurocysticercosis patients has shown the presence
of substance P positive cells adjacent to degenerating worms,
and this neuropeptide is expressed in granulomas in murine
models of neurocysticerosis (Robinson et al., 2002). Interestingly,
administration of substance P into the rodent hippocampus
can induce seizures, and levels of substance P correlate with
granuloma formation and seizure activity in animal models
of CNS helminth infection. Furthermore, substance P/NK-1R
interactions are required for cytokine responses and seizures
associated with neurocysticerosis granulomas (Garza et al.,
2008, 2010). Human African trypanosomiasis also affects
the CNS and substance P has similarly been implicated in
the neuropathology of this protozoan parasite. Inhibition of
substance P/NK-1R interactions using the non-peptide NK-1R
antagonist RP-67580 reduces the inflammatory response and
the reactive astrogliosis associated with Trypanosoma brucei
brucei infection of the CNS (Kennedy et al., 1997), further
supporting a role for substance P/NK-1R interactions in
neuroinflammation associated with eukaryotic parasite CNS
infections.
Bacterial infections of the CNS are serious and often
intractable conditions affecting the meninges and the brain
parenchyma. During bacterial meningitis, increased cellularity
and reactive astrogliosis are hallmarks of an active immune
response within the CNS. Such responses indicate activation
of resident astrocytes and the accumulation of cells at the site
of bacterial challenge, either due to proliferation of glial cells
including microglia, or the recruitment of peripheral leukocytes.
Furthermore, the recruitment and/or activation of resident
glial cells and infiltrating leukocytes are associated with high
CNS levels of inflammatory mediators resulting in neurological
dysfunction. Using mice deficient in the expression of NK-1R
or the prophylactic administration of the NK-1R antagonist
L703,606, we have demonstrated that substance P interactions
with NK-1R are required for the increases in blood-brain
barrier permeability, astrogliosis, increased CNS cellularity,
and elevated numbers of microglia/macrophages associated
with infection with the clinically relevant bacterial CNS
pathogens Streptococcus pneumoniae, Neisseria meningitidis and
Borrelia burgdorferi (Chauhan et al., 2008, 2011). Furthermore,
in these studies we have shown that substance P/NK-1R
interactions are involved in bacterially-induced demyelination
and behavioral changes following infection with these
disparate bacterial species. Importantly, the decreases in
bacterial-induced CNS disease severity seen with NK-1R
inhibition or deficiency were associated with diminished
CNS production of key inflammatory mediators including
IL-6 and TNF-α, and the prevention of infection-induced
decreases in the level of the anti-inflammatory cytokine
IL-10.
Interestingly, bacterial infection in these mouse models is
associated with elevated levels of NK-1R expression in the
brain and, specifically, by microglia and astrocytes (Chauhan
et al., 2011). Such increases are particularly important since
we have shown that substance P can significantly increase
bacteria induced IL-6 production by microglia (Chauhan et al.,
2008). Furthermore, this neuropeptide can augment microglial
expression of the pro-inflammatory enzyme cyclooxygenase-2
and its product prostaglandin E2, and elevate expression of
the prostanoid receptors EP2 and EP4 to further potentiate
inflammation (Rasley et al., 2004b). Together, these animal
studies indicate a pivotal role for substance P in the initiation and
progression of damaging neuroinflammation following bacterial
infection of the CNS.
Frontiers in Cellular Neuroscience | www.frontiersin.org 5 January 2017 | Volume 10 | Article 296
Johnson et al. Targeting NK-1R to Limit Neuroinflammation
Similarly, intense CNS inflammation can occur following viral
infection and a relationship between substance P and human
immunodeficiency virus (HIV) infection has been suggested.
Elevated levels of substance P have been observed in the serum
of HIV infected patients and simian immunodeficiency virus-
infected rhesus macaques (Douglas et al., 2001, 2008a,b; Lai et al.,
2001; Vinet-Oliphant et al., 2010). Viral levels correlate with the
amount of substance P released by immune cells and it has been
suggested that this neuropeptide may facilitate viral replication
by increasing the expression of receptors including CCR5 that
are required for HIV infection of host cells (Bost, 2004a; Manak
et al., 2010). In the CNS, human fetal brain cells have been
shown to express NK-1R and interactions between this receptor
and substance P appear to exacerbate HIV-1 infection (Schwartz
et al., 2013).
Finally, substance P interactions with NK-1R have been
associated with CNS disorders that are generally associated with
sterile inflammation such as Alzheimer’s disease, Parkinson’s
disease, multiple system atrophy (MSA) and multiple sclerosis
(MS). However, it seems that this influence may center on
the neuroprotective effects of this neurokinin. Decreased levels
of substance P have been reported in animal models of
CNS motor disorders and in the brain tissue of postmortem
Parkinson’s disease patients (Chen et al., 2004). Similarly,
in Alzheimer’s disease, reduced levels of substance P are
observed in the cortical regions of postmortem brain tissues
and in patient cerebrospinal fluid (Quigley and Kowall,
1991; Kowall et al., 1993; Waters and Davis, 1997; Raffa,
1998). Furthermore, in MSA and Parkinson’s disease patients
there is severe depletion of NK-1R expressing neurons in
the ventrolateral medulla (Benarroch et al., 2003). But even
this apparently benign role may have a darker side as
substance P immunoreactive astrocytes have been identified
in MS plaques (Kostyk et al., 1989), and a requirement
for substance P/NK-1R interactions has been reported for
the maintenance of chronic inflammation in experimental
autoimmune encephalomyelitis (EAE) mouse models of MS
(Reinke et al., 2006). Such a detrimental role is also supported
by genome-wide linkage studies identifying the TAC1 gene
encoding the substance P precursor protein as a possible MS
susceptibility gene (Vandenbroeck et al., 2002; Cunningham
et al., 2007).
Together, the available data indicate that interactions between
substance P and NK-1R dictate the inflammatory response
observed in diverse CNS infections or disorders. Additionally,
the amount of substance P released by neurons and immune
cells, along with the number of available receptors, determines
the level of neuroinflammation, as greater release of substance P
permits diffusion of this neuropeptide to more distal binding
sites broadening its effect (Abbadie et al., 1996; Doyle and Hunt,
1999; Mantyh, 2002).
SUBSTANCE P AS A DOUBLE-EDGED
SWORD IN CNS IMMUNE RESPONSES
An active immune response can be protective as well as
detrimental in the CNS. While infiltrating leukocytes and
resident glia play a role in limiting infection and trauma-
associated damage, immune responses generated by these events
may prove detrimental if not controlled and limited at the
appropriate time (Douglas and Leeman, 2011). Indeed, multiple
neurodegenerative disorders are associated with exacerbated
immune responses by resident and recruited cells in the brain.
Therefore, a delicate balance needs to be struck in order to limit
the generation of damaging inflammation within the CNS.
For some bacterial and viral infections, substance P has
been demonstrated to be necessary for clearance. For example,
murine gammaherpesvirus 68 has been demonstrated to increase
the expression of substance P and its receptor in mucosal
and lymphoid organs. Importantly, NK-1R deficient mice
show reduced CTL responses and IL-12 secretion, resulting in
increased viral burden compared to wild type animals (Elsawa
et al., 2003). Similarly, substance P/NK-1R interactions are
required for resistance to Salmonella infection as demonstrated
by the advanced salmonellosis and reduced survival rates in
infected mice treated with an NK-1R antagonist (Kincy-Cain
and Bost, 1996, 1997). Here again, substance P promotes IL-12
expression and this leads to IFN-γ production that drives
the cell-mediated immunity required to clear this intracellular
bacterial pathogen.
In contrast, this neuropeptide appears to contribute to
disease pathology for some infectious agents. For example,
substance P increases the bronchoconstriction and damaging
cardiac inflammation following infection with respiratory
syncytial virus and encephalomyocarditis virus, respectively
(Bost, 2004b; Robinson et al., 2009). Likewise, substance P
contributes to the severity of inflammation associated with
Trypanosoma brucei infection and inflammation and granuloma
size in a mouse model of Taenia solium cysticercosis (Kennedy
et al., 1997; Garza et al., 2008, 2010).
As we discussed earlier, our data suggest that substance P
similarly exacerbates damaging inflammation within the CNS
to disparate bacterial pathogens. We determined that the
absence of substance P/NK-1R interactions in substance P
receptor deficient mice or prophylactic pharmacological
NK-1R inhibition in wild type animals significantly reduces
bacteria-induced neuroinflammation and resultant CNS
damage (Chauhan et al., 2008, 2011). NK-1R null mice and
mice treated with an NK-1R antagonist showed reduced
inflammatory and maintained immunosuppressive cytokine
production, as well as decreased astrogliosis, cellularity and
demyelination following intracerebral administration of
the Gram negative bacterial pathogens N. meningiditis and
B. burgdorferi, or the Gram positive bacterium S. pneumoniae
(Chauhan et al., 2008, 2011). These animal studies therefore
indicate that substance P/NK-1R interactions are essential for
the progression of damaging inflammation following bacterial
CNS infection.
Targeting NK-1R also has the potential to ameliorate CNS
disorders that are thought to involve sterile inflammation
given the presence of substance P immunoreactive glia in
MS plaques (Kostyk et al., 1989) and the reported ability
of the non-peptide NK-1R antagonist SR140333 to attenuate
chronic inflammation associated with mouse models of MS
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(Reinke et al., 2006). However, the benefit of inhibiting
substance P/NK-1R interactions in other neurological disorders,
including Alzheimer’s disease and Parkinson’s disease, is more
equivocal due to the reported neuroprotective properties of this
neuropeptide and/or its ability to stimulate non-amyloidogenic
amyloid precursor protein processing (as discussed in Chen et al.,
2004; Severini et al., 2016).
As such, the available data suggests that substance P
contributes to neuroprotection during some degenerative
CNS disorders and to beneficial cell-mediated host responses
against viruses and intracellular bacteria facilitating pathogen
clearance. Inhibiting substance P/NK-1R interactions in these
conditions would likely compromise the protective effects of
this neuropeptide and exacerbate disease severity. In contrast,
NK-1R-mediated augmentation of glial and recruited leukocyte
immune responses appears to be detrimental during extracellular
bacterial and parasite infections of the CNS, and perhaps MS,
by exacerbating neuroinflammation and neurological damage
(as summarized in Table 1). Based on these studies, it
appears that targeting substance P/NK-1R interactions might
be a promising strategy to ameliorate the inflammatory CNS
damage associated with such infectious agents and neurological
disorders.
THE THERAPEUTIC POTENTIAL OF NK-1R
ANTAGONISTS IN INFLAMMATORY CNS
DISORDERS
The involvement of tachykinins in a wide range of pathological
processes has made them an attractive target for therapeutic
intervention, and the pharmaceutical industry has initiated the
development of additional NK-1R antagonists (as discussed in
Quartara and Altamura, 2006; Quartara et al., 2009). Many
of these NK-1R antagonists have reached phase II and III
clinical trials with one, aprepitant, currently approved by
the United States Food and Drug Administration (Quartara
and Altamura, 2006; Quartara et al., 2009; Di Fabio et al.,
2013). The non-peptide NK-1R antagonist CP-96,345 has been
reported to downregulate constitutive substance P mRNA
expression in human mononuclear cells (Lai et al., 2002)
and the ability of such NK-1R antagonists to treat a range
of gastrointestinal, respiratory and urogenital, and sensory
disorders has been explored. However, the utility of next
generation NK-1R antagonists in the treatment of CNS
conditions including nausea, addiction, pain, and depression, has
been of particular interest due to their ability to cross the blood-
brain barrier.
The first NK-1R antagonists were developed in the
early 1990s, but most were not effective as analgesics and
anti-depressants as they could not efficiently cross the blood-
brain barrier. An exception to this rule was LY303870, which
was shown to block rodent licking behavior in the late
stages of persistent nociceptive activation with inhibition of
ex vivo substance P binding to both peripheral and central
NK-1R (Iyengar et al., 1997). Subsequently, an analysis of
the pharmacokinetics of the non-peptide NK-1R antagonist
ezlopitant in dogs revealed the presence of this compound
and its two pharmacologically active metabolite compounds in
cerebrospinal fluid following intravenous or oral administration,
indicating its ability to cross the blood brain barrier (Reed-Hagen
et al., 1999). Of the latest generation of NK-1R antagonists,
aprepitant has been shown to cross the blood-brain barrier
after oral administration using human positron emission
tomography to demonstrate its ability to occupy NK-1R
within the brain in an oral dose and plasma concentration
dependent manner (Bergström et al., 2004). Similarly, the
NK-1R antagonist casopitant, when radioactively labeled, has
been demonstrated to be rapidly absorbed into the bloodstream
and can subsequently be found within the brain (Ruhlmann
and Herrstedt, 2009). This antagonist has completed phase II
and III clinical trials and has similar success to aprepitant in
the treatment of chemotherapy-induced nausea and vomiting
(Ruhlmann and Herrstedt, 2009), but this drug has not
yet received United States Food and Drug Administration
approval.
The ability of NK-1R antagonists to cross the blood-brain
barrier means that these agents have the potential for use
in the treatment in wide range of CNS disorders. Indeed,
TABLE 1 | Models of neuroinflammation in which NK-1R antagonists and/or genetic deficiency have shown reduced disease severity.
CNS disorder Model Organism Antagonist Knockout Effect Reference
Neurocysticersosis T. crassiceps Mouse NK-1R
Substance P
Lower granuloma volume.
Less IL-1β, IL-6, TNF-α.
Garza et al. (2010)
African trypanosomiasis T. brucei + diminazene Mouse RP-67580 Reduced astrogliosis,
clinical score, cellularity.
Kennedy et al. (1997)
Bacterial meningitis S. pneumoniae
N. meningiditis
B. burgdorferi
Mouse L703,606 NK-1R Reduced BBB permeability,
astrogliosis, microgliosis,
cellularity, demyelination,
IL-6, TNF-α. More IL-10.
Chauhan et al. (2008)
Chauhan et al. (2011)
Multiple sclerosis EAE Mouse SR 14033 NK-1R Greater mobility.
Decreased MOG
specific T-cells.
Reinke et al. (2006)
CP-96,345 Less clinical and
histological signs.
Nessler et al. (2006)
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FIGURE 1 | Substance P-mediated exacerbation of neuroinflammatory damage following central nervous system (CNS) infection. Conserved microbial
motifs are recognized by Toll-like receptor (TLR) and NOD-like receptors (NLR) pattern recognition receptors (PRR) expressed by perivascular macrophages, microglia
and astrocytes leading to NF-kB activation and inflammatory and/or neurotoxic mediator production. Substance P (SP) released by neurons and perhaps activated
glia acts on neurokinin-1 receptor (NK-1R) bearing CNS cells to augment NF-kB activation or function to enhance glial responses. Local inflammation promotes the
recruitment of leukocytes to the site of infection that will, in turn, recognize microbial components and produce more pro-inflammatory and neurotoxic mediators.
Infiltrating leukocytes such as monocytes/macrophages, dendritic cells and lymphocytes express NK-1R and so are similarly susceptible to the pro-inflammatory
actions of substance P. Importantly, inflammatory cytokines can also augment the expression of PRR and NK-1R by glia and leukocytes, and can elevate local
production of substance P. This positive feedback loop would be anticipated to increase the sensitivity of host cells to pathogen components and sensitize
leukocytes and glia to this neuropeptide, thereby exacerbating inflammatory damage. Intervention with pharmaceutical NK-1R inhibitors capable of penetrating the
blood-brain barrier would prevent substance P mediated exacerbation of glial and leukocyte inflammatory responses, and interrupt such a feedback loop.
aprepitant and its pro-drug fosaprepitant are currently employed
as post-chemotherapy anti-emetic agents (Aapro et al., 2015).
Likewise, casopitant has completed phase II and phase III
trials and has similar success to aprepitant in the treatment
of chemotherapy-induced nausea and vomiting (Ruhlmann and
Herrstedt, 2009). In addition to use as an anti-emetic, there
has been promising research that aprepitant and other NK-1R
antagonists may have efficacy against other CNS disorders
including depression. The NK-1R antagonist MK-869 has been
shown to effectively suppress depressive behavior in guinea
pigs, and both MK-869 and casopitant successfully completed
phase II clinical trials to treat depression (Kramer et al.,
1998; Ebner and Singewald, 2006; Di Fabio et al., 2013).
However, it must be noted that MK-869 failed in a phase
III trial to treat major depressive disorder (Keller et al.,
2006).
Frontiers in Cellular Neuroscience | www.frontiersin.org 8 January 2017 | Volume 10 | Article 296
Johnson et al. Targeting NK-1R to Limit Neuroinflammation
There are also hopes that NK-1R antagonists may be
valuable for the treatment of other CNS disorders as diverse
as schizophrenia, panic attacks, Parkinson’s disease, and MS.
This hope stems from the promising effects of NK-1R
antagonists capable of crossing the blood-brain barrier in
animal models of such disorders (Table 1). For example, the
NK-1R antagonist SR140333 has shown efficacy as a co-therapy
with other anti-inflammatory agents in ameliorating myelin
oligodendrocyte glycoprotein-induced EAE, a mouse model
of MS (Reinke et al., 2006). Similarly, CP 96345, has also
been demonstrated to reduce EAE severity, and this effect was
associated with stabilization of the blood brain barrier as well as
reduced T-helper type 1 immunity (Nessler et al., 2006).
Importantly, given a potential role for substance P/NK-1R
interactions in damaging inflammatory responses within
the CNS following infection, there is considerable interest
in targeting this receptor to limit neuroinflammation and
neurological sequelae associated with infectious agents
(Table 1). For example, since direct hippocampal substance P
administration elicits seizures in mice and an NK-1R antagonist
has been shown to prevent seizure activity in a rodent model
of helminth brain infection (Robinson et al., 2012), it is
possible that blocking the actions of this neuropeptide may
prove useful in neurocysticercosis patients. Furthermore, our
own studies have shown that pharmacological targeting of
NK-1R with the antagonist L703,606 can not only prevent the
development of damaging inflammation due to streptococcal
CNS infection when administered prophylactically, but can also
reverse infection-associated gliosis and demyelination when
delivered therapeutically without increasing CNS bacterial
burden (Chauhan et al., 2011).
While further studies are clearly needed to define the specific
mechanisms underlying the ability of substance P to augment
CNS inflammation and its role in pathogen clearance, the
available data raise the intriguing possibility that currently
approved NK-1R antagonists, such as aprepitant, could be
repurposed for use as a co-therapy to limit neuroinflammatory
damage associated with infectious agents and certain
neurodegenerative conditions. The use of such agents might have
considerable advantages over other anti-inflammatory agents
such as corticosteroids, non-steroidal anti-inflammatory drugs,
prostaglandin inhibitors, and P2X7 antagonists, by limiting
excessive inflammation without broadly attenuating host
immune responses that may be required to resolve infection.
Continued research on the ability of NK-1R antagonists to
alleviate these health conditions may therefore yield new
treatment options for patients with CNS infections, and perhaps
other inflammatory neurological disorders.
CONCLUDING REMARKS
Infectious and sterile CNS disorders are often associated
with overwhelming and damaging inflammation due to the
immune responses of resident CNS cells and infiltrating
leukocytes. Currently, neuroinflammatory diseases such as
meningitis are treated with corticosteroids in combination
with antibacterial, antiviral, or antifungal agents (Aberdein and
Singer, 2006; Hoffman and Weber, 2009). Corticosteroids
have both anti-inflammatory and immunosuppressive
properties and treatment with these agents has been shown
to reduce the risk of hearing loss and mortality due to
meningitis. However, the immunosuppressive properties of
corticosteroids may interfere with the ability of the body
to clear infections, especially if the antibiotics used are not
effective or antiviral medications are not available (Fitch and
van de Beek, 2008). Furthermore, corticosteroid treatment
can lead to adverse effects including the development of
ulcers, myopathy, and bone loss, or central effects including
sleep disorders and mood swings. As such, there is a current
need for new treatment options to limit neuroinflammation
associated with infection of the CNS and neurodegenerative
conditions.
Substance P is produced at high levels in the CNS, and
its target receptor NK-1R is expressed by resident CNS
cells including microglial and astrocytes, and by immune
cells that can infiltrate the CNS such as macrophages and
lymphocytes. Importantly, this tachykinin functions both as a
neurotransmitter and an immunomodulator, and substance P is
recognized to exacerbate inflammatory responses at peripheral
sites including the skin, lung and gastrointestinal and urogenital
tracts. In infectious and sterile CNS conditions associated
with severe neuroinflammation, substance P/NK-1R interactions
appear to augment inflammation by increasing the release of
inflammatory mediators while concomitantly decreasing the
production of anti-inflammatory cytokines from microglia and
astrocytes (as summarized in Figure 1) thereby exacerbating
neuronal damage (Chauhan et al., 2008, 2011). Our own studies
indicate that therapeutic intervention with NK-1R antagonists
can limit neuroinflammation, reactive gliosis and demyelination
in a mouse model of streptococcal meningitis (Chauhan
et al., 2011) while other groups have shown efficacy of these
agents in animal models of MS (Nessler et al., 2006; Reinke
et al., 2006). This data therefore supports the use of NK-1R
receptor antagonists in the treatment of such neuroinflammatory
disorders.
The latest generation of NK-1R antagonists can be delivered
orally and can readily cross the blood-brain barrier. Importantly,
these antagonists exert central effects and the NK-1R antagonist,
aprepitant, is approved for use as an anti-emetic agent in patients
receiving chemotherapy. As such, the repurposing of currently
available NK-1R antagonists may yield alternative co-therapy
options for CNS inflammation associated with extracellular
bacteria and parasites, and perhapsMS, withmore specificity and
reduced adverse effects.
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